BioArctic AB's (publ) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
The Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for the ...
Eisai (ESALY) and Biogen (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk in Mexico has approved humanized ...
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk ...
Mexican health authority approves Leqembi for the treatment of early Alzheimer’s disease: Tokyo Friday, December 6, 2024, 14:00 Hrs [IST] Eisai Co., Ltd. and Biogen Inc. announc ...
Eisai (ESALY) and Biogen (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk in Mexico has approved humanized anti-soluble aggregated amyloid-beta monoclonal ...